68 Views
Tuesday Poster Session
Category: Practice Management
Abhishek Verma, MD
New York University School of Medicine
New York, NY, United States
| Heart Transplant (n=58) | Liver Transplant (n=65) | Lung Transplant (n=68) | Renal Transplant (n=109) | P-Value | ||
Age, median (IQR) | 59.7 (40.1-68.0) | 61.0 (39.0-66.3) | 61.7 (53.7-69.0) | 53.9 (42.0-65.0) | 0.161 | ||
Female, n (%) | 22 (37.9) | 22 (33.8) | 37 (54.4) | 50 (45.9) | 0.081 | ||
Race, n (%) | | | | < 0.001 | |||
White | 31 (53.4) | 37 (56.9) | 52 (76.5) | 27 (24.8) | | ||
Black | 9 (15.5) | 7 (10.8) | 8 (11.8) | 32 (29.4) | | ||
Asian | 6 (10.3) | 2 (3.1) | 1 (1.5) | 13 (11.9) | | ||
Other/Mixed | 2 (3.4) | 4 (6.2) | 3 (4.4) | 16 (14.7) | | ||
Unknown | 10 (17.2) | 15 (23.1) | 4 (5.9) | 21 (19.3) | | ||
Ethnicity, n (%) | | | | | 0.097 | ||
Non-Hispanic | 36 (62.1) | 42 (64.6) | 56 (82.4) | 67 (61.5) | | ||
Hispanic | 11 (19.0) | 10 (15.4) | 8 (11.8) | 21 (19.3) | | ||
Other/Declined/Unknown | 11 (19.0) | 13 (0.20) | 4 (5.9) | 21 (19.3) | | ||
Human Immunodeficiency Virus (HIV), n (%) | 0 (0) | 3 (4.6) | 0 (0) | 3 (2.8) | 0.161 | ||
Charlson’s Comorbidity Index, median (IQR) | 4 (3-5) | 4 (3-6) | 3 (2.75-5) | 4 (3-6) | 0.007 | ||
Symptoms at Test, n (%) | | | | | | ||
| Hematochezia | 0 (0) | 0 (0) | 1 (1.5) | 3 (2.8) | 0.342 | |
| Abdominal Pain | 13 (22.4) | 20 (30.8) | 14 (20.6) | 24 (22.0) | 0.496 | |
| Fever | 11 (19.0) | 15 (23.1) | 14 (20.6) | 26 (23.9) | 0.884 | |
| Nausea/Vomiting | 11 (19.0) | 10 (15.4) | 12 (17.6) | 31 (28.4) | 0.145 | |
| Other/Unknown | 1 (1.7) | 2 (3.1) | 8 (11.8) | 0 (0) | < 0.001 | |
Travel 30 Days Prior to Test, n (%) | 4 (6.9) | 3 (4.6) | 1 (1.5) | 5 (4.6) | 0.514 | ||
Sexual Exposure, n (%) | 0 (0) | 10 (15.4) | 0 (0) | 2 (1.8) | 0.526 | ||
Recent Antibiotics or Hospitalization, n (%) | 30 (51.7) | 33 (50.8) | 50 (73.5) | 53 (48.6) | 0.009 | ||
On Opportunistic Infection Prophylaxis, n (%) | 18 (31.0) | 20 (30.8) | 54 (79.4) | 51 (46.8) | < 0.001 | ||
Place of Test, n (%) | | | | | 0.012 | ||
| Outpatient | 15 (25.9) | 16 (24.6) | 14 (20.6) | 37 (33.9) | | |
| Inpatient | 43 (74.1) | 46 (70.8) | 54 (79.4) | 63 (57.8) | | |
| ED | 0 (0) | 3 (4.6) | 0 (0) | 9 (8.3) | | |
Hospitalized, n (%) | 44 (75.9) | 44 (67.7) | 53 (77.9) | 63 (57.8) | 0.019 | ||
Length of Stay, median (IQR) | 6 (2-11) | 9 (4-18) | 8.5 (6-24.3) | 6 (4-10) | 0.006 | ||
Duration of Transplant, median (IQR) | 2392 (612-5270) | 1280 (245-2806) | 643 (120-2404) | 711 (162-2364) | 0.004 | ||
Transplant Age > 1 Year, n (%) | 47 (81.0) | 42 (64.6) | 40 (58.8) | 69 (63.3) | 0.05 | ||
Immunosuppression, n (%) | | | | | | ||
| None | 1 (1.7) | 1 (1.5) | 0 (0) | 4 (3.7) | 0.387 | |
Calcineurin Inhibitor | 56 (96.6) | 56 (86.2) | 66 (97.1) | 97 (89.0) | 0.046 | ||
Mycophenolate Mofetil/Azathioprine | 34 (58.6) | 37 (56.9) | 56 (82.4) | 91 (83.5) | < 0.001 | ||
| Steroids | 45 (77.6) | 31 (47.7) | 67 (98.5) | 78 (71.6) | < 0.001 | |
| mTOR Inhibitor | 9 (15.6) | 9 (13.8) | 1 (1.5) | 2 (1.8) | < 0.001 | |
| Other | 0 (0) | 3 (4.6) | 4 (5.9) | 5 (4.6) | 0.361 | |
Immunosuppression Held, n (%) | 13 (23.2) | 6 (9.2) | 8 (11.8) | 21 (19.3) | 0.124 | ||
Number of Immunosuppressive Agents, n (%) | | | | | < 0.001 | ||
| 1 | 3 (5.2) | 19 (29.2) | 0 (0) | 10 (9.2) | | |
| 2 | 25 (43.1) | 21 (32.3) | 13 (19.1) | 32 (29.4) | | |
| 3 | 28 (48.3) | 24 (36.9) | 52 (76.5) | 65 (59.6) | | |
| 4 | 2 (3.4) | 1 (1.5) | 3 (4.4) | 2 (1.8) | | |
Positive GI Panel, n (%) | 24 (41.4) | 18 (27.7) | 17 (25.0) | 59 (54.1) | < 0.001 | ||
Viral infection, n (%) | 12 (20.7) | 6 (9.2) | 11 (16.2) | 26 (23.9) | 0.100 | ||
Bacterial Infection, n (%) | 13 (22.4) | 14 (21.5) | 6 (8.8) | 37 (33.9) | 0.002 | ||
Parasitic Infection, n (%) | 0 (0) | 0 (0) | 2 (2.9) | 4 (3.7) | 0.224 | ||
Multiple Pathogens, n (%) | 6 (10.3) | 5 (7.7) | 2 (2.9) | 10 (9.2) | 0.588 | ||
Viral Infection, n (%) | | | | | | ||
| Adenovirus | 1 (1.7) | 0 (0) | 0 (0) | 0 (0) | 0.242 | |
| Astrovirus | 0 (0) | 0 (0) | 0 (0) | 1 (0.92) | 0.624 | |
| Norovirus | 8 (13.8) | 5 (7.7) | 8 (11.8) | 20 (18.3) | 0.241 | |
| Rotavirus | 1 (1.7) | 1 (1.5) | 2 (2.9) | 0 (0) | 0.408 | |
| Sapovirus | 2 (3.4) | 1 (1.5) | 2 (2.9) | 4 (3.7) | 0.877 | |
Bacterial Infection, n (%) | | | | | | ||
| Campylobacter | 2 (3.4) | 0 (0) | 0 (0) | 4 (3.7) | 0.180 | |
| Clostridioides difficile | 10 (17.2) | 8 (12.3) | 10 (14.7) | 20 (18.3) | 0.739 | |
| Plesiomonas shigelloides | NA | NA | NA | NA | NA | |
| Salmonella spp. | NA | NA | NA | NA | NA | |
| Yersinia enterocolitica | 0 (0) | 2 (3.1) | 0 (0) | 0 (0) | 0.064 | |
| Vibrio parahaemolyticus | 0 (0) | 0 (0) | 1 (1.5) | 1 (0.92) | 0.661 | |
| Vibrio vulnificus | NA | NA | NA | NA | NA | |
| Vibrio cholerae | NA | NA | NA | NA | NA | |
| Enteroaggregative E. coli (EAEC) | 2 (3.4) | 4 (6.2) | 1 (1.5) | 5 (4.6) | 0.560 | |
| Enteropathogenic E. coli (EPEC) | 8 (13.8) | 7 (10.8) | 0 (0) | 17 (15.6) | 0.009 | |
| Enterotoxigenic E. coli (ETEC) | 2 (3.4) | 0 (0) | 0 (0) | 1 (0.92) | 0.182 | |
| Shiga-like toxin-producing E. coli (STEC) | 0 (0) | 1 (1.5) | 0 (0) | 2 (1.8) | 0.526 | |
| E. coli O157 | NA | NA | NA | NA | NA | |
| Shigella/Enteroinvasive E. coli (EIEC) | 0 (0) | 1 (1.5) | 0 (0) | 0 (0) | 0.305 | |
Parasitic Infection, n (%) | | | | | | ||
| Cryptosporidium | 0 (0) | 1 (1.5) | 0 (0) | 2 (1.8) | 0.526 | |
| Cyclospora cayetanensis | NA | NA | NA | NA | NA | |
| Entamoeba histolytica | NA | NA | NA | NA | NA | |
| Giardia lamblia | 0 (0) | 0 (0) | 3 (4.4) | 2 (1.8) | 0.156 | |
Antibiotics Prescribed, n (%) | 40 (69.0) | 39 (60.0) | 44 (64.7) | 69 (63.3) | 0.775 | ||
| Empiric Antibiotic Therapy | 25 (36.8) | 31 (47.7) | 37 (54.4) | 40 (36.7) | 0.010 | |
| Directed Antibiotic Therapy | 16 (27.6) | 9 (13.8) | 8 (11.8) | 41 (37.6) | < 0.001 | |
Hospitalization Within 30 Days of PCR, n (%) | 8 (13.8) | 10 (15.4) | 10 (14.7) | 21 (19.3) | 0.769 | ||
ER Visit Within 30 Days of PCR, n (%) | 2 (3.4) | 3 (4.6) | 1 (1.5) | 4 (3.7) | 0.776 | ||
Surgery Within 30 Days of PCR, n (%) | 1 (1.7) | 3 (4.6) | 7 (10.3) | 7 (6.4) | 0.225 | ||
Death Within 30 Days of PCR, n (%) | 9 (15.5) | 9 (13.8) | 12 (17.6) | 8 (7.3) | 0.185 | ||
Endoscopy Within 30 Days of PCR, n (%) | 4 (6.9) | 15 (23.1) | 2 (2.9) | 11 (10.1) | 0.001 |